SPONSOR
Henan Cancer Hospital
Total Trials
8
Recruiting
8
Phases
Phase 2, Phase 1, Phase 2, Phase 3
Conditions studied: LymphomaGene AbnormalityAcute Myeloid LeukemiaMaintenance TreatmentMinor Residue DiseaseInterferon-α-1bInterleukin-2ThalidomideVenentoclaxAzacitidine
Henan Cancer Hospital is a clinical research sponsor with 8 registered studies on ClinicalTrials.gov, of which 8 are actively recruiting participants. Research covers conditions including Lymphoma, Gene Abnormality, Acute Myeloid Leukemia, Maintenance Treatment.
The trial portfolio spans Phase 2, Phase 1, Phase 2, Phase 3 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Henan Cancer Hospital
How many clinical trials has Henan Cancer Hospital sponsored?
ClinicalMetric currently tracks 8 clinical trials sponsored by Henan Cancer Hospital, of which 8 are actively recruiting participants. These trials cover conditions including Lymphoma, Gene Abnormality, Acute Myeloid Leukemia. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Henan Cancer Hospital research focus on?
Henan Cancer Hospital clinical trials span Lymphoma, Gene Abnormality, Acute Myeloid Leukemia, Maintenance Treatment, Minor Residue Disease, and additional conditions. The research pipeline includes Phase 2, Phase 1, Phase 2, Phase 3 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Henan Cancer Hospital clinical trial?
To participate in a Henan Cancer Hospital trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Henan Cancer Hospital trials with current recruitment status updated daily.
Clinical Trials by Henan Cancer Hospital
NCT04263935
Recruiting
Correlation Between Driver Gene Abnormalities and Clinicopathological Characteristics and Disease Prognosis in Lymphoma
Lymphoma
NCT06256627
Recruiting
The Maintenance Treatment of "ITIVA" in AML Patients
Acute Myeloid Leukemia
NCT06749730 Phase 2
Recruiting
Adebrelimab Combined with Apatinib and Gemcitabine and Cisplatin (GP) First-line Treatment for Unresectable Biliary Tract Carcinoma
Unresectable Biliary Tract Carcinoma
NCT07037576
Recruiting
Efficacy and Safety of Prepectoral Prosthesis Immediate One-Stage Breast Reconstruction Versus Two-Stage Expander/Prosthesis Reconstruction in Postoperative Adjuvant Radiotherapy Breast Cancer Patients: A Prospective, Single-Center, Cohort Study
Breast Cancer Patients
NCT05468970
Recruiting
Study on Clinical Features, Treatment Mode and Survival of Bone and Soft Tissue Tumors
Bone and Soft Tissue Tumors
NCT07334431 Phase 1, Phase 2
Recruiting
Fruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Patients With HER2-positive Advanced Gastric Cancer
Gastric Adenocarcinoma
NCT04280822 Phase 3
Recruiting
Neo-adjuvant Immunochemotheray Versus Neo-adjuvant Chemotherapy for Resectable Esophageal Carcinoma
Esophageal Cancer
NCT06176534 Phase 2
Recruiting
Combination Followed by Maintenance Chemotherapy Versus CDK4/6 Inhibitor Combined With Endocrine Therapy for HR Low/HER2-negative Advanced Breast Cancer: a Prospective, Randomized, Open-label Phase Ⅱ Clinical Trial
Advanced Breast Cancer
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology